Algernon Pharmaceuticals Inc.

04/22/2024

Chronic Kidney Disease (CKD) is when the kidneys are damaged or cannot filter blood as well as healthy kidneys, often due to fibrosis.

Here is how NP-251 (Repirinast) can help treat this disease ➡️ https://bit.ly/49x1ZTU

04/17/2024

The Australian Therapeutic Goods Administration (TGA) has launched a Medicines Repurposing Program (MRP) to broaden treatment options. This initiative is dedicating $10.1M for repurposing efforts over four years.

Read more on this great initiative! ⬇️

Quality care experts say GPs should consider a new TGA program looking to expand prescribing criteria and medicine access, but there are caveats.

04/09/2024

We were pleased to receive the latest notice of intention to grant from the Chinese Patent Office for the patent application for its antifibrotic drug candidate NP-251 (Repirinast).

Check out what our CEO says about this great development ➡️ https://bit.ly/49uM3Bf

04/01/2024

🔬AI's Impact on Drug Discovery

Traditional drug discovery can be a long and expensive process, with low success rates. Advanced machine learning is transforming the field. By analyzing extensive biological and clinical data, it predicts drug interactions, adverse effects, and uncovers repurposing opportunities.

Read more on these advancements!

An artificial intelligence framework could push the boundaries of drug discovery by rapidly revealing new clinical indications for pre-existing drugs.

03/19/2024

💊What are the benefits of repurposing drugs?

From Alzheimer's to multiple sclerosis, and various rare diseases, several drugs have been discovered and repurposed for their treatment.

Learn more here ⬇️

Repurposed drugs are especially effective in the treatment of rare diseases

03/13/2024

Chronic cough is a persistent condition that can last for several weeks for children and adults.

Learn more on how NP-120 (Ifenprodil) could help in the treatment for Chronic cough ➡️ https://bit.ly/3qV6I0L

03/04/2024

Due to the limited efficacy of traditional treatments for chronic disability following traumatic brain injury (TBI), the emergence of ibogaine, a novel psychedelic substance, shows promise in managing these conditions.

In a study of 30 male US military veterans with TBI, 83% experienced improvements in mental health, processing speed, problem-solving, and working memory.

Read more on this here ⬇️

Military veterans with traumatic brain injury saw drastic reductions in depression and symptoms of post-traumatic stress disorder after using the psychedelic drug ibogaine

02/26/2024

: Repirinast, Algernon’s top candidate for treating Chronic Kidney Disease (CKD), has shown promising results with a 51% reduction in fibrosis and complementary effects alongside telmisartan.

Algernon’s drug repurposing program prioritizes IP protection through patent filings covering methods of use, dosing, formulations, and novel salt forms.

Stay updated on our program's progress here! https://bit.ly/49uM3Bf

02/20/2024

After years of research, the FDA's draft guidance is now illuminating the field of psychedelic research.

In June, the FDA released a draft guidance aimed at assisting researchers exploring the therapeutic potential of psychedelic drugs for various medical conditions. This is the first guidance of its kind, providing essential considerations for designing clinical trials involving psychedelic substances.

Learn more here ⬇️

The foundation laid by Johns Hopkins has, over the last 20 years, spurred a wave of interest — and progress — into the benefits of psychedelic medicines.

02/12/2024

We are pleased to announce the receipt of a notice of allowance from the Japanese Patent Office titled: 'Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis (IPF).'

Check out what our CEO says about this great development ➡️ https://bit.ly/3tXUQws

02/06/2024

: Ifenprodil is a targeted NMDA receptor antagonist, specifically focusing on GluN2B. The NMDA receptor is present in various tissues, including lung cells, T-cells, neutrophils, and certain types of cancer cells.

🧬Algernon has been granted a notice of allowance for the patent application aimed at treating Idiopathic Pulmonary Fibrosis with Ifenprodil. By repurposing this drug, they aspire to address not only IPF but also interstitial lung disease.

Get more details here ➡️ https://bit.ly/3tXUQws

02/01/2024

Artificial intelligence and machine learning (AI/ML) are transforming pharmaceutical research, transforming drug discovery, repurposing, clinical testing, and productivity.

Algernon focuses on the drug repurposing model to provide a cost-effective and capital-efficient way to discover new uses for drugs.

Learn more about how AI is revolutionizing this industry! ➡️

Artificial intelligence and machine learning will revolutionize pharmaceutical research including clinical trials

01/31/2024

NEWS RELEASE: We are pleased to report that Algernon (CSE: AGN | FRANKFURT: AGW | OTCQB: AGNPF) has received a notice of intention to grant from the Chinese Patent Office for its anti-fibrotic drug candidate NP-251 (Repirinast).

Repirinast is Algernon’s leading candidate for the treatment of renal fibrosis and kidney disease, and will be the company’s second patented medication in China.

Check out the full press release 👉 https://bit.ly/3OlZMSX

01/29/2024

: DMT is a naturally occurring psychedelic compound that is part of the tryptamine family.

🩺 Algernon NeuroScience is pioneering the testing of DMT as a potential treatment for ischemic stroke and traumatic brain injury with a Phase 2a trial in planned.

Learn more ➡️ https://bit.ly/48Jf8IH

01/22/2024

Algernon is pleased to announce the receipt of a notice of allowance from the Japanese Patent Office titled: 'Compositions and Methods for Treating Idiopathic Pulmonary Fibrosis (IPF).'

This patent covers the treatment of interstitial lung disease, encompassing idiopathic pulmonary fibrosis, using the drug ifenprodil.

For more information ➡️ https://bit.ly/3tXUQws

01/17/2024

Traumatic brain injuries (TBI) and strokes are major global causes of disability. Despite medical advances, psychedelics show promise in rapidly improving neurobehavioral outcomes in similar conditions.

Algernon NeuroScience is dedicated to researching and advancing psychedelic DMT to aid individuals affected by stroke and TBI.

Learn more about the research into this treatment ➡️

Acquired brain injury (ABI), such as traumatic brain injury and stroke, is a leading cause of disability worldwide, resulting in debilitating acute and chronic symptoms, as well as an increased risk of developing neurological and neurodegenerative disorders. These symptoms can stem from various neur...

01/08/2024

We are delighted to have been issued a patent through the United States Patent and Trademark Office (USPTO) for the treatment of three diseases with its drug repirinast.

Here is what our CEO has to say about this great development! https://bit.ly/3vn5MnJ

01/03/2024

Algernon is delighted to share we have been issued a patent through the United States Patent and Trademark Office (USPTO) for the treatment of fatty liver disease (NAFLD), including steatohepatitis (NASH), and NASH-derived hepatocellular carcinoma.

For More - https://bit.ly/3vn5MnJ